Collaboration, License and Purchase Agreements - Narrative (Details) - USD ($)		1 Months Ended		12 Months Ended
	Oct. 24, 2014	Jun. 30, 2015	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Service and other product revenue				$ 2,813,000	$ 3,715,000	$ 1,313,000
Research and development				27,860,000	11,893,000	8,372,000
Valeant Pharmaceuticals North America LLC Co-Promotions Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Service and other product revenue				347,000	3,357,000	1,109,000
Durect Development and License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development				$ 4,572,000	4,251,000	599,000
Minimum future milestone payments						$ 103,000,000
Royalty agreement term						15 years
Aradigm Corporation Asset Purchase Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty rate			3.00%	3.00%
Expected amortization expense, 2016				$ 286,000
Expected amortization expense, 2017				286,000
Expected amortization expense, 2018				286,000
Expected amortization expense, 2019				286,000
Expected amortization expense, 2020				286,000
Expected amortization expense, thereafter				857,000
Brabant Pharma Limited [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate amount of contingent liabilities	$ 95,000,000
Regulatory Milestones [Member] | Brabant Pharma Limited [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate amount of contingent liabilities	50,000,000
Sales Milestones [Member] | Brabant Pharma Limited [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate amount of contingent liabilities	$ 45,000,000
Migranal [Member] | Sales Revenue, Services, Net [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract termination payment		$ 500,000
Minimum [Member] | Durect Development and License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Annual external development expense obligation						$ 1,000,000
Royalty Agreements [Member] | Sumavel DosePro [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amortization of Intangible Assets				$ 345,000	$ 591,000	$ 1,242,000